CRLX101

Key FDA Decisions and Trial Results Expected in October
24/7 Wall St
Tue, 10/4/16 - 10:07 am
FDA
clinical trials
Exelixis
cabozantinib
Cobimetinib
Celldex Therapeutics
CDX-011
Cerulean Pharma
CRLX101
Medivation
Xtandi
Palatin
bermelanotide
Rexahn
RX-3117
Anthera Pharmaceuticals
Key FDA Decisions and Trial Results Expected in October
24/7 Wall St
Thu, 09/8/16 - 09:50 am
FDA
clinical trials
cabozantinib
Cobimetinib
Exelixis
Medivation
Xtandi
Celldex Therapeutics
glemba
Palatin
bremelanotide
CRLX101
Cerulean Pharma
Anthera Pharmaceuticals
Following another PhII failure, cash-strapped Cerulean chops half its staff
Endpoints
Fri, 08/19/16 - 11:30 am
Cerulean Pharma
clinical trials
layoffs
CRLX101
Cerulean pitches $75M IPO to give its cancer drug another shot
Fierce Biotech
Tue, 03/11/14 - 08:45 am
IPOs
Cerulean
CRLX101